Clinical Trials
21 trialsNCT04037254 2026-05-20
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT04295577 2026-05-13
MONITOR-UK
Royal Marsden NHS Foundation Trust
Completed
NCT04313504 2026-05-07
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
University of Cincinnati
Phase 2 Completed
NCT04475939 2026-05-01
ZEAL-1L
GlaxoSmithKline
Phase 3 Completed
NCT05021562 2026-04-13
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Takeda
Completed
NCT03601923 2026-03-25
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT06086665 2026-02-04
REFIRM
Asan Medical Center
Completed
NCT04481113 2026-01-29
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT04991480 2026-01-27
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1 Completed
NCT03869190 2026-01-22
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1/2 Completed
NCT02854436 2025-12-22
Galahad
Janssen Research & Development, LLC
Phase 2 Completed
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT03404960 2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2 Completed
NCT04080284 2025-08-19
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
Phase 2 Completed
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04493060 2025-08-07
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Completed
NCT03326193 2025-07-31
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
Phase 2 Completed
NCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed